Literature DB >> 18791165

Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

P K Epling-Burnette1, Lubomir Sokol, Xianhong Chen, Fanqi Bai, Junmin Zhou, Michelle A Blaskovich, JianXiang Zou, Jeffrey S Painter, Todd D Edwards, Lynn Moscinski, Jeffrey A Yoder, Julie Y Djeu, Said Sebti, Thomas P Loughran, Sheng Wei.   

Abstract

Large granular lymphocyte (LGL) leukemia is commonly associated with poor hematopoiesis. The first case of pulmonary artery hypertension (PAH) was observed in a 57-year-old woman with natural killer (NK)-LGL leukemia and transfusion-dependent anemia. Using a genetic approach, we demonstrated that killing of pulmonary endothelial cells by patient NK cells was mediated by dysregulated balance in activating and inhibitory NK-receptor signaling. Elevated pulmonary artery pressure and erythroid differentiation improved after disrupting the NK-receptor signaling pathway with 4 courses of a farnesyltransferase inhibitor, tipifarnib. Coincidental association between PAH and LGL leukemia suggest a causal relationship between the expanded lymphocyte population and these clinical manifestations. This trial is registered at www.ClinicalTrials.gov as NCI 6823.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791165      PMCID: PMC2597136          DOI: 10.1182/blood-2008-02-136382

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  NK cells in innate immunity.

Authors:  Jessica A Hamerman; Kouetsu Ogasawara; Lewis L Lanier
Journal:  Curr Opin Immunol       Date:  2005-02       Impact factor: 7.486

2.  Association of DAP12 with activating CD94/NKG2C NK cell receptors.

Authors:  L L Lanier; B Corliss; J Wu; J H Phillips
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

Review 3.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

Review 4.  Arousal and inhibition of human NK cells.

Authors:  L L Lanier; B Corliss; J H Phillips
Journal:  Immunol Rev       Date:  1997-02       Impact factor: 12.988

5.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Authors:  S Bauer; V Groh; J Wu; A Steinle; J H Phillips; L L Lanier; T Spies
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

6.  Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes.

Authors:  Evan C Howe; Marcin Wlodarski; Edward J Ball; Lisa Rybicki; Jaroslaw P Maciejewski
Journal:  Exp Hematol       Date:  2005-11       Impact factor: 3.084

7.  Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias.

Authors:  Zachary P Nearman; Marcin Wlodarski; Anna M Jankowska; Evan Howe; Yadira Narvaez; Edward Ball; Jaroslaw P Maciejewski
Journal:  Br J Haematol       Date:  2006-11-30       Impact factor: 6.998

8.  Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy.

Authors:  L J Rossoff; J Genovese; M Coleman; D R Dantzker
Journal:  Chest       Date:  1997-08       Impact factor: 9.410

9.  ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL).

Authors:  Pearlie K Epling-Burnette; Fanqi Bai; Sheng Wei; Pratima Chaurasia; Jeffrey S Painter; Nancy Olashaw; Andrew Hamilton; Said Sebti; Julie Y Djeu; Thomas P Loughran
Journal:  Oncogene       Date:  2004-12-09       Impact factor: 9.867

10.  Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor-associated protein (KARAP)/DAP-12.

Authors:  E Tomasello; L Olcese; F Vély; C Geourgeon; M Bléry; A Moqrich; D Gautheret; M Djabali; M G Mattei; E Vivier
Journal:  J Biol Chem       Date:  1998-12-18       Impact factor: 5.157

View more
  16 in total

1.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 2.  T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.

Authors:  Rebecca J Watters; Xin Liu; Thomas P Loughran
Journal:  Leuk Lymphoma       Date:  2011-07-13

Review 3.  Natural killer-cell neoplasms.

Authors:  John P Greer; Claudio A Mosse
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

4.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

5.  Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

Authors:  Elina Parri; Heikki Kuusanmäki; Daria Bulanova; Satu Mustjoki; Krister Wennerberg
Journal:  Blood Adv       Date:  2021-04-13

Review 6.  Large granular lymphocytic leukemia: a brief review.

Authors:  Ekta Rahul; Aparna Ningombam; Shreyam Acharya; Pranay Tanwar; Amar Ranjan; Anita Chopra
Journal:  Am J Blood Res       Date:  2022-02-15

Review 7.  Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.

Authors:  Francis Leblanc; Dan Zhang; Xin Liu; Thomas P Loughran
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

Review 8.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

9.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.

Authors:  Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Koskela; Francis Leblanc; Kwok Peng Ng; Thomas Olson; Bartlomiej Przychodzen; Manuel Afable; Ines Gomez-Segui; Kathryn Guinta; Lisa Durkin; Eric D Hsi; Kathy McGraw; Dan Zhang; Marcin W Wlodarski; Kimmo Porkka; Mikkael A Sekeres; Alan List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

10.  Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.

Authors:  Fanqi Bai; Alejandro V Villagra; Jianxiang Zou; Jeffrey S Painter; Kirby Connolly; Michelle A Blaskovich; Lubomir Sokol; Said Sebti; Julie Y Djeu; Thomas P Loughran; Sheng Wei; Eduardo Sotomayor; Pearlie Epling-Burnette
Journal:  Cancer Immunol Immunother       Date:  2011-10-09       Impact factor: 6.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.